Vertex Pharmaceuticals key statistics and ratios

In fiscal 2025, Vertex Pharmaceuticals had return on equity of 22.5% and a net margin of 32.9%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Vertex Pharmaceuticals: financial ratios, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Net margin	−630.3%	−526.3%	2.1%	−7.0%	−36.7%	−127.2%	−53.9%	−6.6%	10.6%	68.8%	28.3%	43.7%	30.9%	37.2%	36.7%	−4.9%	32.9%	35.0%
Return on equity	−58.6%	−94.3%	4.6%	−12.0%	−37.8%	−60.8%	−55.2%	−10.7%	16.5%	64.9%	22.4%	36.7%	24.9%	27.7%	23.0%	−3.2%	22.5%	22.6%
Return on assets	−32.8%	−41.0%	1.5%	−4.3%	−17.5%	−31.7%	−23.0%	−4.2%	8.2%	42.7%	16.1%	27.0%	18.6%	21.0%	17.7%	−2.4%	16.4%	16.6%
Effective tax rate	—	—	31.9%	−0.9%	—	—	—	—	—	—	15.6%	13.0%	14.2%	21.5%	17.4%	—	14.9%	16.5%
R&D as % of revenue	540.1%	444.6%	50.2%	50.2%	72.8%	147.4%	96.5%	61.5%	53.2%	46.5%	42.1%	29.5%	40.3%	28.4%	32.0%	32.9%	32.6%	31.0%
SG&A as % of revenue	127.8%	131.0%	28.4%	28.3%	29.4%	52.6%	36.5%	25.4%	19.9%	18.3%	15.8%	12.4%	11.1%	10.6%	11.5%	13.3%	14.6%	16.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Vertex Pharmaceuticals: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Net margin	37.7%	31.4%	23.3%	34.8%	35.2%	37.3%	34.5%	33.0%
R&D as % of revenue	31.6%	34.3%	35.4%	33.0%	31.8%	30.5%	32.2%	29.8%
SG&A as % of revenue	13.4%	13.0%	14.3%	14.3%	14.5%	15.3%	16.5%	17.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 3 checks passed · June 30, 2026

What it owns · $27.4bn

Short-term assets $12.5bnLonger-term assets $14.9bn

What it owes, and who funded it · $27.4bn

Short-term liabilities $3.9bnLonger-term liabilities $3.2bnShareholders' equity $20.2bn

Short-term assets cover short-term liabilities $12.5bn of assets due within a year against $3.9bn of liabilities due within a year.
Short-term assets cover long-term liabilities $12.5bn short-term assets against $3.2bn of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of $4.8bn against $13m of interest.

From Vertex Pharmaceuticals's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

76 /100

Strong moat

How hard Vertex Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 20 / 20

Cash operating profit has been a median 37.3% of total assets over 9 years.
Pricing power 20 / 20

Gross margin has been a median 87.3%, moving by 0.8 percentage points (standard deviation) across 9 years.
Durability 10 / 20

Operating margin has been a median 34.1%; its worst year was -3.4%.
Cash conversion 19 / 20

Free cash flow was positive in 9 of 10 years, at a median 31.4% of revenue.
Discipline 12 / 20

The diluted share count fell 2.4% over five years; stock-based pay has been a median 6.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (81 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BIIB vs VRTX REGN vs VRTX INCY vs VRTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vertex Pharmaceuticals.